We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study.
- Authors
Van Voorhees, A.S.; Stein Gold, L.; Lebwohl, M.; Strober, B.; Sofen, H.; Papp, K.; Bagel, J.; Zhang, Z.; Paris, M.; Wang, Y.
- Abstract
In summary, the STYLE phase III study supports apremilast as an effective treatment for scalp psoriasis in different types of patients, including those with scalp psoriasis inadequately controlled by other therapies. During the extension phase, patients initially randomized to placebo were switched to apremilast [placebo/apremilast (P/A) group; with titration during week 16] and patients initially randomized to apremilast continued active treatment [apremilast/apremilast (A/A) group; with dummy titration during week 16] through week 32. Achievement of Numeric Rating Scale (NRS)-Scalp Itch and NRS-Whole Body Itch response was maintained at week 32 in patients continuing with apremilast and observed in patients initially randomized to placebo after switching to apremilast.
- Subjects
PATIENT safety; SCALP; PSORIASIS; PSORIATIC arthritis; SEBORRHEIC dermatitis
- Publication
British Journal of Dermatology, 2021, Vol 185, Issue 4, p840
- ISSN
0007-0963
- Publication type
Article
- DOI
10.1111/bjd.20083